Europe Plasmid Dna Contract Manufacturing Market Size & Outlook
Related Markets
Europe plasmid dna contract manufacturing market highlights
- The Europe plasmid dna contract manufacturing market generated a revenue of USD 77.2 million in 2023.
- The market is expected to grow at a CAGR of 19.4% from 2024 to 2030.
- In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
- Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 77.2 million |
| Market revenue in 2030 | USD 267.1 million |
| Growth rate | 19.4% (CAGR from 2023 to 2030) |
| Largest segment | Cell & gene therapy |
| Fastest growing segment | Cell & Gene Therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cell & Gene Therapy, Immunotherapy |
| Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
Other key industry trends
- In terms of revenue, Europe region accounted for 23.8% of the global plasmid dna contract manufacturing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 203.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasmid DNA Contract Manufacturing Market Scope
Plasmid DNA Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Esco Aster | View profile | 11-50 | Singapore, Central Region, Singapore, Asia | https://escoaster.com |
| PlasmidFactory | View profile | 11-50 | Bielefeld, Nordrhein-Westfalen, Germany, Europe | https://plasmidfactory.com/ |
| VGXI | View profile | 101-250 | The Woodlands, Texas, United States, North America | https://vgxii.com/ |
| Viva Biotech | View profile | 1001-5000 | Shanghai, Shanghai, China, Asia | http://www.vivabiotech.com.cn/ |
| BioCina | View profile | 101-250 | Thebarton, South Australia, Australia, Oceania | https://www.biocina.com/ |
| TriLink BioTechnologies | View profile | 251-500 | San Diego, California, United States, North America | http://www.trilinkbiotech.com/ |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Charles River Laboratories International Inc | View profile | 21400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | https://www.criver.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Lonza Group Ltd | View profile | 18000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | https://www.lonza.com |
Europe plasmid dna contract manufacturing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60.23% in 2023. Horizon Databook has segmented the Europe plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The growing use of pDNA in the biopharmaceutical sector, especially for vaccines and treatments for a wide range of serious illnesses, is a key factor propelling demand in the market. In addition, government spending in the healthcare industry and growth in the elderly population would also contribute to the rise in demand for pDNA contract manufacturing in the region.
According to an article by McKinsey & Company, there is a significant demand for cell & gene therapies in Europe. The anticipated patient population for just four CGT-addressed indications is 385,000, or almost three times the size of the comparable U.S. cohort.
As shown in the figure below, the absolute unmet needs for CGTs in Europe are estimated to clearly exceed that in the U.S. The European Union authorities are keen to support novel therapies that focus on disease areas that are currently undertreated.
Reasons to subscribe to Europe plasmid dna contract manufacturing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe plasmid dna contract manufacturing market databook
-
Our clientele includes a mix of plasmid dna contract manufacturing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe plasmid dna contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Europe plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe plasmid dna contract manufacturing market size, by country, 2018-2030 (US$M)
Europe Plasmid DNA Contract Manufacturing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
